{
  "docId": "019dd923-5f69-752d-a9b6-0d0782a66fef",
  "docSlug": "GU7tHQNbAVEJiBcjPEiK",
  "documentTitle": "See the pitch deck that Compass Pathways used to raise $80 million and fuel its rise into one of the world's biggest psychedelics companies",
  "authorId": "Pitchdecks",
  "authorName": "Compass Pathways",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "strategy_consulting",
  "sourceTypeLabel": "Strategy consulting",
  "presentationDate": null,
  "orientation": "landscape",
  "aspectRatio": 1.333,
  "pageNumber": 8,
  "pageCount": 28,
  "prevPage": 7,
  "nextPage": 9,
  "slideType": "why_now",
  "function": "argue_timing",
  "density": "overcrowded",
  "nDataPoints": 3,
  "notes": "The slide uses a checkmark list format to emphasize key value drivers.",
  "elementsJson": [
    "action_title",
    "bullet_list",
    "footnote"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-5f69-752d-a9b6-0d0782a66fef/8",
  "deckHref": "/decks/019dd923-5f69-752d-a9b6-0d0782a66fef",
  "deckJsonHref": "/decks/019dd923-5f69-752d-a9b6-0d0782a66fef.json",
  "deckAnchorHref": "/decks/019dd923-5f69-752d-a9b6-0d0782a66fef#slide-8",
  "components": [
    {
      "bbox": {
        "h": 0.07,
        "w": 0.88,
        "x": 0.06,
        "y": 0.58
      },
      "kind": "list",
      "text": "Safe substance: Low harm and dependence potential and no significant adverse events in studies",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "06ba3adb-6cef-40fe-a63f-fe79f118f4f4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.13,
        "w": 0.88,
        "x": 0.06,
        "y": 0.33
      },
      "kind": "list",
      "text": "FDA 'Breakthrough Therapy Designation' received in Oct2018: “Preliminary clinical evidence indicates the drug may demonstrate substantial improvement over existing therapies to treat a serious or life threatening disease or condition”",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1b8ab5ee-af42-4e7f-998d-022ba00ba7f4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.13,
        "w": 0.88,
        "x": 0.06,
        "y": 0.68
      },
      "kind": "list",
      "text": "Strong IP position: Never registered as new chemical entity (NCE) and strong protection from four independent sets of patent claims filed in UK/PCT*/US in Oct2018; market protection from generics for 8-11 years in EU, 5-7.5 years in US",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "42b05780-bd0e-4f60-930d-37cf2d60ec50",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.11,
        "w": 0.88,
        "x": 0.06,
        "y": 0.19
      },
      "kind": "list",
      "text": "Value Proposition: Attractive therapeutic, patient, and economic benefit profile, with over 70% of patients rank psilocybin therapy among top 5 most meaningful experiences of their lives",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cd843621-06b8-4f5a-b33b-f2b91de315d0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.07,
        "w": 0.88,
        "x": 0.06,
        "y": 0.48
      },
      "kind": "list",
      "text": "Promising clinical evidence: Strong signals from Phase I/IIa studies by top research institutions in EU and US",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f77fa522-ba6a-4399-97c8-91ec6578f118",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "quote",
      "text": "Preliminary clinical evidence indicates the drug may demonstrate substantial improvement over existing therapies to treat a serious or life threatening disease or condition",
      "attrs": null,
      "subkind": null,
      "toolName": "Authority citation",
      "toolSlug": "authority-citation",
      "confidence": null,
      "componentId": "019dd952-9d68-761b-a001-c61ca213f416",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.25,
        "x": 0.06,
        "y": 0.92
      },
      "kind": "source-note",
      "text": "* PCT = Patent Cooperation Treaty\nSource: 1. Griffiths et al (2016)",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "419444f7-794b-4e0b-9f12-04409203a4ab",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.11,
        "w": 0.88,
        "x": 0.06,
        "y": 0.03
      },
      "kind": "title",
      "text": "Breakthrough Therapy: Psilocybin presents significant scientific and commercial opportunity",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "44b33df4-95b7-469c-ad59-731e47e168e3",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "list-presentation",
      "slug": null,
      "matchId": "0f3f9209-894a-4c67-a9fa-3ad34443b72f",
      "evidence": "The slide uses a bulleted list with checkmarks to present key arguments.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [
    {
      "to": 10,
      "from": 8,
      "name": "Why Now",
      "slug": "15-why-now",
      "bestFor": "Sales pitches, fundraising, requesting immediate budget approval",
      "matchId": "5fd4f8fd-e571-4d26-a411-84655b36503b",
      "evidence": "Slides 8-10 discuss the breakthrough therapy designation and its implications for faster access to patients.",
      "position": 1,
      "objective": "Explain why psilocybin therapy is a timely solution",
      "structure": "The Context (Trends) -> The Trigger Event -> The Window of Opportunity",
      "confidence": 0.7,
      "description": "Create temporal urgency by proving that the window of opportunity is opening or closing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}